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The cancer stem cell (CSC) hypothesis postulates that tumors are maintained by a self-re-
newing CSC population that is also capable of differentiating into non-self-renewing cell
populations that constitute the bulk of the tumor. Although, the CSC hypothesis does
not directly address the cell of origin of cancer, it is postulated that tissue-resident stem
or progenitor cells are the most common targets of transformation. Clinically, CSCs are
predicted to mediate tumor recurrence after chemo- and radiation-therapy due to the rel-
ative inability of these modalities to effectively target CSCs. If this is the case, then CSC
must be efficiently targeted to achieve a true cure. Similarities between normal and malig-
nant stem cells, at the levels of cell-surface proteins, molecular pathways, cell cycle quies-
cence, and microRNA signaling present challenges in developing CSC-specific therapeutics.
Approaches to targeting CSCs include the development of agents targeting known stem cell
regulatory pathways as well as unbiased high-throughput siRNA or small molecule screen-
ing. Based on studies of pathways present in normal stem cells, recent work has identified
potential “Achilles heals” of CSC, whereas unbiased screening provides opportunities to
identify new pathways utilized by CSC as well as develop potential therapeutic agents.
Here, we review both approaches and their potential to effectively target breast CSC.
ª 2010 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.1. What is a cancer stem cell? capacity to differentiate into the non-self-renewing cells,The term “cancer stem cell” has led to a degree of confusion
within the cancer research field; however, while the term is
“imperfect” it is here to stay (Clarke et al., 2006). The existence
of CSC does not imply that these cells are necessarily derived
from normal tissue stem cells. Rather, the definition of “can-
cer stem cells” is based on three functional characteristics of
these cells. These include the ability to initiate tumors in im-
munocompromised or syngeneic mice, self-renewal capacity
measured by tumor formation in secondary mice, and the1; fax: þ1 734 647 9271.
. Wicha).
ation of European Biochewhich constitute the tumor bulk. Formal proof that a tumor
follows the CSC paradigm is based on the ability to prospec-
tively isolate fractions of cells with these properties as well
as fractions depleted of these properties. On the other hand,
the inability to fractionate cells with these properties suggests
the tumor may not be hierarchically organized and each cell
has equal tumor-initiation potential determined by intrinsic
and/or extrinsic factors (Dick, 2008). Given these properties,
especially the ability to initiate tumors in model organisms,
and confusion surrounding the term “cancer stem cell”, wemical Societies. Published by Elsevier B.V. All rights reserved.
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“tumor-initiating cell”.
Stem cells can exhibit multiple fates: division, differentia-
tion, quiescence, or death (Dick, 2008). A hallmark of stem
cells is their ability to self renew whereby cell fate (i.e. tu-
mor-initiation) is segregated symmetrically or asymmetrically
to daughter cells, which can be functionally defined by sec-
ondary transplantation (Dick, 2003; McKenzie et al., 2006).
Asymmetric segregation of cell membranes, proteins, and
even DNA impact cell fate, especially in stem cells
(Neumuller and Knoblich, 2009). The existence of multiple
stem cell populations with varying self-renewal capacity has
been demonstrated in the hematopoietic system (Majeti
et al., 2007; McKenzie et al., 2006).
The third property of CSC is the ability to differentiate into
the bulk, non-tumorigenic cells. Work from the great patholo-
gists over the last 100years (Virchow,Maximov, etc) has shown
tumors aremorphologically heterogeneous, composed of rela-
tively undifferentiated and differentiated cells. Seminal work
byPierceandcolleaguesdemonstrated spontaneousdifferenti-
ation of malignant teratocarcinoma cells into mature benign
cells (Pierce et al., 1960). Similarities in the heterogeneity of tu-
morsandnormal tissue led to theproposalof cancerasacarica-
ture of normal development, albeit with altered differentiation
(Pierce and Speers, 1988). Cellular heterogeneity is typically
measured using differential expression of protein differentia-
tionmarkers (i.e. CD44, CD24, CD34, CD38, etc) and is generated
in xenograft models upon serial transplantation. The ability to
harness this differentiation process as a therapy has been suc-
cessfully demonstrated by the treatment of acute promyelo-
cytic leukemia with all-trans retinoic acid (Nowak et al., 2009).2. Brief history of CSCs
While the formal description of cancer stemcells is a relatively
recent development, the concept is an old one related to tis-
sue-resident stem cells, especially in the hematopoietic sys-
tem (Dick, 2008). After the demonstration by Furth and Kahn
in 1937 that a single murine leukemia cell could initiate a tu-
mor inmice (Furth andKahn, 1937), work over the last 70 years
has shown a wide variation of tumor-initiation frequency.
Surprisingly, human studies where single cell suspensions
of cancers were autotransplanted back into the patient
showed tumor-initiation was rare and required more than
106 cells (Southam et al., 1962).
In the 1960s, amajor conceptual developmentwas thedem-
onstration that the three major lineages of the blood system
are derived from one common precursor stem cell
(McCullochandTill, 1960), tumors exhibited functional hetero-
geneity (Clarkson et al., 1970), and a small subset of acute my-
eloid leukemia (AML) cells proliferate slower than the mature
blast cells (Clarkson, 1969). These studies laid the groundwork
for the seminal discovery of AML stem cells by John Dick and
colleagues in 1994 (Lapidot et al., 1994). Technical advances, in-
cluding the development of NOD/SCID (non-obese diabetic/se-
vere combined immune deficiency) immunocompromised
mousemodels (Shultz et al., 2007, 1995), monoclonal antibody
production (Spangrude et al., 1988), and fluorescent activated
cell sorting (FACS) (Bonner et al., 1972) provided the toolsneeded to demonstrate that engraftment of primary AML cells
in immunocompromised mice is mediated by a rare cell that
can be prospectively isolated. Further discoveries showed
AML is clonally derived, hierarchically organized, and can be
serially passaged in immunocompromised mice (Bonnet and
Dick, 1997; Hope et al., 2004).
Until the identification of CSCs in human breast cancer in
2003 (Al-Hajj et al., 2003), the applicability of these observa-
tions to solid cancers remained hotly debated. In the follow-
ing years, CSCs have been identified in most solid cancers,
including brain, colon, pancreatic, head and neck, and others
(Li et al., 2007; O’Brien et al., 2007; Prince et al., 2007; Singh
et al., 2004). However, xenotransplantation studies have in-
herent problems, including the foreign microenvironment,
incompatible growth factor and cytokine signals, and the
lack of immune cells in these models. This raises very impor-
tant points that must be addressed. Indeed, some human
cancers, such as melanoma, may not follow the CSC para-
digm with an inability to prospectively isolate tumor-initiat-
ing cells and a high frequency of tumor-initiation (Kelly
et al., 2007; Quintana et al., 2008). Recently, Roesch et al. sug-
gest that in melanoma a slow-cycling subpopulation may
play an important role in tumor “maintenance” rather than
initiation and that this may represent a “dynamic” rather
than static state (Roesch et al., 2010). However, it has been
shown in syngeneic studies in human (Southam et al., 1962)
and mice (Cho et al., 2008; Huntly et al., 2004; Yilmaz et al.,
2006; Zhang et al., 2008) that not all cancer cells can reinitiate
the tumor suggesting that all the work from xenotransplanta-
tion studies cannot be summarily disregarded. Importantly,
the CSC paradigm does not depend solely on the frequency
of tumor-initiating cells, but rather the evidence of functional
heterogeneity and hierarchal organization (Dick, 2008;
Kennedy et al., 2007).3. Hierarchal organization of the human breast
Thehumanbreast is composedofabranchingnetworkofducts
terminating in small ductal structures termed terminal ductal
lobular units (TDLU). The ducts contain luminal epithelial and
myoepithelial cells while fibroblast, endothelial, adipocytes,
and hematopoietic cells constitute the remaining stromal
component. The luminal lineage is divided into ductal and al-
veolar cells that line theducts or thealveolar units presentdur-
ing pregnancy, whereas the myoepithelial cells are basal,
contractile cells surrounding the ducts that force secreted
milk proteins through the ductal network to the nipple during
lactation. The large expansion of breast epithelium during pu-
berty andmultiple pregnancies suggests the existence of cells
with extensive proliferative and regenerative properties typi-
cally associated with stem cells (Visvader, 2009).
Observational studies have provided additional lines of ev-
idence for breast stem cells. Women exposed to radiation as
teenagers, such as atomic bomb survivors, have an increased
risk of developing breast cancer later in life, suggesting the
presence of long-lived cells (Land and McGregor, 1979). Exam-
ination of X-linked inactivation and loss of heterozygosity in
normal and adjacent breast cancer tissue showed large tracts
of epithelial cells sharing similar chromosomal alterations
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et al., 1996; Tsai et al., 1996).
The seminal development of the in vivo mouse mammary
fat pad transplant system by DeOme et al. provided an assay
to study breast stem cell function and remains the “gold stan-
dard” (DeOme et al., 1959). In this assay, the epithelial portion
in the pre-pubertal mammary fat pad is surgically removed
leaving the stromal portion. Donor cells are transplanted
into this “cleared fat pad” and outgrowths are quantified. Us-
ing this assay, it was demonstrated that outgrowths could be
generated from different regions of the mouse mammary
gland, young and old virgin or pregnant mice, and the out-
growths could be serially transplanted for multiple genera-
tions (Daniel et al., 1968; Daniel and Young, 1971; Smith and
Medina, 1988; Young et al., 1971). Retroviral marking of mam-
mary cells conclusively proved mammary outgrowths could
be derived from a single cell (Kordon and Smith, 1998). Kuper-
wasser et al. further improved the transplant assay for human
breast epithelial cells by “humanizing” the fat pad via injec-
tion of irradiated human fibroblasts, which generated a stro-
mal environment that more closely simulates human breast
tissue (Kuperwasser et al., 2004). Recently, Eirew et al. devel-
oped an alternative in vivo method for quantifying human
breast stem cell activity based on transplantation of cells em-
bedded in collagen gels into the renal capsule of mice supple-
mented with estrogen and progesterone (Eirew et al., 2008).
The development of these in vivo transplant assays has fa-
cilitated the prospective isolation of mouse and human breast
stem and progenitor cells based on various cell-surface
markers. Mouse stem cells are enriched in the
CD49fhiCD29hiCD24þSca1 fraction (Shackleton et al., 2006;
Stingl et al., 2006). Human breast stem cells have been found
to be contained in the CD49fhiEpCAM (Eirew et al., 2008;
Lim et al., 2009) and aldehyde dehydrogenase (ALDH)þ frac-
tions (Ginestier et al., 2007). Breast cancer stem cells are found
in the CD44þCD24 fractionwith as few as 200 cells able to ini-
tiate tumors (Al-Hajj et al., 2003). Luminal progenitor cells
within the human breast have been identified using in vitro
differentiation assays and exhibit a CD49fþEpCAMþ pheno-
type (Eirew et al., 2008; Lim et al., 2009). Myoepithelial progen-
itor cells were concentrated in the CD49fþEpCAM/low fraction
alongwith bi-potent progenitors (Eirew et al., 2008). Basal cells
aremarked by CD49fþEpCAM expression whereasmature lu-
minal cells are mainly CD49fEpCAMþ (Lim et al., 2009). Addi-
tionally, recent studies have suggested that ductal and
alveolar structures may originate from different stem cells
in the mouse breast (Jeselsohn et al., 2010). Additionally, it
has been shown using in vitro suspension culture that mam-
mosphere formation is a property of breast progenitor cells
(Charafe-Jauffret et al., 2009; Dontu et al., 2003; Ginestier
et al., 2007; Liu et al., 2006).4. What is the cell of origin for breast cancer?
The cell of origin represents an important question in cancer
research and has implications for prevention, early detection,
and treatment. The quiescent, hence relatively long-lived, na-
ture of stem cells has been suggested as important in allowing
these cells to acquire the multiple genetic lesions required fortumorigenesis (Reya et al., 2001). The cell-of-origin hypothesis
postulates that cells within a tissue acquire some initial hit(s),
somatic or germ-line, but only the stem cell survives by virtue
of its quiescent program and eventually passes the mutation
(s) to progeny cells when it self-renews. On the other hand,
progenitor cells, with limited self-renewal capacity, may gen-
erate cancers through acquisition of self-renewal capacity. Ex-
perimental evidence for both possibilities has been
demonstrated by the generation of murine leukemias after in-
troduction of leukemogenic oncogenes into purified hemato-
poietic stem cells or progenitor cells (Cozzio et al., 2003;
Krivtsov et al., 2006; Somervaille and Cleary, 2006). Armstrong
and colleagues showed reactivation of self-renewal pathways
in normal progenitors led to transformation (Krivtsov et al.,
2006). However, in these studies, stem cells were more effi-
ciently transformed and, thus, the most common target may
be the stem cell.
Parallel studies comparing the transformation efficiency of
mouse mammary progenitor and stem cells with mammary
oncogenes, such asWnt-1, have not been possible until the re-
cent description and isolation of these subsets (Eirew et al.,
2008; Lim et al., 2009; Shackleton et al., 2006; Stingl et al.,
2006). Ectopic Wnt-1 expression has been shown to increase
mammary stem and progenitor cells in pre-neoplastic tissue
suggesting Wnt-1 may alter the epithelial hierarchy and
MMTV-Wnt-1 tumors contain cells capable of multi-lineage
differentiation whereas MMTV-Neu tumors are composed of
luminal committed cells suggesting these tumors originate
from different cells in the mammary hierarchy (Liu et al.,
2004; Vaillant et al., 2008). However, these descriptive studies
cannot distinguish if Wnt-1 more efficiently transforms stem
or progenitor cells. In the mouse, Bouras et al. demonstrated
constitutive Notch activation in the stem or luminal progeni-
tor cells induced similar pre-neoplastic lesions at comparable
frequency suggesting Notch signaling can transform either
population (Bouras et al., 2008).
Breast cancer is a histologically, molecularly and epidemi-
ologically heterogeneous disease. There are six molecular
subtypes based on gene expression analysis, which include
normal breast-like, luminal A and B, basal-like, claudin-low,
and HER2/ERBB2 over-expressing (Herschkowitz et al., 2008,
2007; Perou et al., 2000; Sorlie et al., 2001; Troester et al.,
2006). The molecular heterogeneity between breast cancers
has been suggested to result from different targets of transfor-
mation. Lim and colleagues examined the different epithelial
populations in normal and pre-neoplastic tissue from BRCA1
mutation carriers (Lim et al., 2009). In women heterozygous
for BRCA1 mutations, they reported an increase in luminal
progenitor cells and these tumors weremolecularlymore sim-
ilar to luminal progenitors than the stem cell enriched popu-
lation. These results seemingly contrast with an earlier
study showing an expansion of breast stem cells after
siRNA-mediated knockdown of BRCA1 in normal mammary
epithelial cells (Liu et al., 2008). However, these observations
suggest a critical role of BRCA1 dosage since BRCA1 expression
is lower in stem cells compared to luminal progenitors and
differentiated luminal cells. Taken together, these data sug-
gest expansion of the stem and/or luminal progenitor popula-
tion may be a target for transformation in BRCA1 mutation
carriers (Ginestier et al., 2009).
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While the existence of CSC in multiple human tumors has
been firmly established, the functional and clinical signifi-
cance of these cells remains hotly debated (Shipitsin and
Polyak, 2008). The idea that CSC might be resistant to treat-
ment had foundations in seminal leukemia studies that pred-
icated relapse and ultimate failure of chemotherapy was due
to the inability to eradicate CSC (Clarkson and Fried, 1971). In-
deed, work from Craig Jordan’s lab showed AML LSC are resis-
tant to the chemotherapeutic cytarabine, which is part of
standard induction therapy (Guzman et al., 2001, 2005). Recent
studies have highlighted the chemo- and radio-resistance of
CSCs in solid tumors as a possible mechanism to explain
why current treatment modalities fail to cure most patients
(Bao et al., 2006; Creighton et al., 2009; Li et al., 2008; Phillips
et al., 2006; Yu et al., 2007). NOTCH and Wnt signaling, path-
ways utilized in normal stem cell self-renewal, were found
to mediate radio-resistance in glioblastoma and breast cancer
(Phillips et al., 2006; Wang et al., 2010; Woodward et al., 2007).
CSCs have been invoked as the seed for distantmetastases,
which typically are responsible for end-stage disease and ulti-
mately death. The epithelialemesenchymal transition (EMT)
process is critical for metastasis. Numerous reports suggest
a link between EMT and CSC (Mani et al., 2008), and recently
the concept of “migrating cancer stem cells” has been pro-
posed (Brabletz et al., 2005). Interestingly, the basal fraction
(CD49fhiEpCAM) containing normal human stem cells and
myoepithelial progenitor cells express the common EMT
marker vimentin suggesting some cells may be undergoing
EMT (Eirew et al., 2008; Lim et al., 2009). However, since this
fraction is not purely stem cells, it remains to be determined
if most or all stem cells express EMT markers. Nonetheless,
given the congruence between EMT factors and stem cell
markers in invasive cancer cells, strategies to target CSC
must also focus these “migrating cancer stem cells.”6. The realities of targeting CSC
The development of CSC-specific agents presents new chal-
lenges for evaluating clinical efficacy (Wang, 2007). The com-
monly accepted criteria for clinical efficacy is overall survival,
but this can only be demonstrated in phase III trials requiring
large patient numbers and long-term follow-up. Phase II trials
are designed to assess a drug’s activity using surrogate end-
points to determine whether a phase III trial is warranted.
The typical endpoint used in phase II trials is tumor shrinkage
using criteriadefinedbyRECIST (Eisenhauer et al., 2009),which
canbemeasuredoverweeksormonths.Thepremise is that tu-
mor regression equates with clinical benefit. Although tumor
shrinkagemay temporarily relieve symptoms related to tumor
burden, a correlation between tumor response and overall sur-
vival has rarely been shown for patients with hematological
and solid cancers (Huff et al., 2006). For example, there is only
a modest overall survival advantage for pancreatic, prostate
and metastatic breast cancer patients treated with combina-
tion chemotherapy even with tumor response (Abratt et al.,
2004; Chung et al., 2008; Rocha Lima et al., 2004). This paradoxbetween response and survival may be explained by an inabil-
ityof chemotherapy toeffectively target theCSC.Theproblems
associated with correlation between tumor response and sur-
vival in phase II/III clinical trials highlight a need for novel clin-
ical trial design to test anti-CSC efficacy. These trials may
utilize surrogate intermediate endpoints evaluating cells
expressing CSCs markers.
One such approach is the use of neoadjuvant trials where
CSC populations from tumor tissue obtained pre- and post-
therapy are assayed in vitro and in vivo (Creighton et al., 2009).
Additionally, there are inherent differences when testing po-
tential anti-CSC therapeutics in the adjuvant and advanced
settings. Agents causing tumor regression in the advanced set-
ting likely reflect effects on thebulk tumorpopulation, butmay
haveminimal effect on the CSC population. In contrast, a CSC-
specific therapeutic would show modest effects on tumor
growthwhen tested in theadvancedsetting, butmayhave sub-
stantial clinical benefit in the adjuvant setting.
An ideal CSC-specific therapeutic would target the CSC and
bulk tumor cells withminimal adverse effects. There aremore
than 500 kinds of adverse effects associated with cancer ther-
apy and range from minor to life threatening or death (Trotti
et al., 2003). Chemotherapy-induced myelosuppression is
a major dose-limiting toxicity (Daniel and Crawford, 2006;
Nirenberg, 2003) and is not limited to chemotherapy regimens;
treatment with the molecularly targeted BCR-ABL inhibitor
imatinib (Gleevec) led to myelosuppression in patients with
chronic myeloid leukemia (CML) or solid tumors (Agis et al.,
2006). Additionally, total body irradiation was shown to selec-
tively induce senescence in mouse hematopoietic stem cells,
as compared to progenitor cells (Wang et al., 2006b). The rela-
tionship between chemotherapy-induced toxicity in other tis-
sues, especially the gastrointestinal, andnormal stemcells has
been demonstrated for numerous regimens (Dekaney et al.,
2009; Ijiri and Potten, 1983, 1987). However, within human
skin, the CD49þCD71low stem cells were more radio-resistant
than the CD49þCD71þ progenitor cells (Rachidi et al., 2007).
Strategies to eradicate breast CSC do not necessarily need to
spare normal breast stem cells since most women diagnosed
with breast cancer are post-menopausal and do not need the
ability to lactate. However, these therapies should not target
other normal stem cells, such as hematopoietic, gastrointesti-
nal, skin, and neuronal, which are critical for patient survival.7. Pathways utilized by solid CSCs
In order to effectively target CSC, a detailed understanding of
the pathways regulating the growth, survival, and self-re-
newal of CSC is needed. For example, seminal studies from
Craig Jordan’s lab first demonstrated a reliance on NF-kB sig-
naling in AML LSC (Guzman et al., 2001), which could be
exploited using parthenolide, a natural product sesquiterpene
lactone from the medicinal plant feverfew (Guzman et al.,
2005). Parthenolide induced apoptosis in the LSC in vitro and
was able to inhibit leukemia engraftment in NOD/SCID mice
after a brief (16 h) treatment in vitro. More importantly, parthe-
nolide had little effect on normal HSC suggesting parthenolide
treatment in AML patients may spare normal blood cell pro-
duction. An orally bioavailable parthenolide analog with
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(Guzman et al., 2007). While NF-kB signaling and sensitivity
to parthenolide may not apply to all CSC, these studies pres-
ent a model for rational drug development for anti-CSC
therapeutics.7.1. New role for an old tumor suppressor: p53
Since the discovery of the p53 tumor suppressor (Hollstein
et al., 1991), there have been thousands of articles detailing
numerous roles of p53 in cancer. A recent article highlights
a newly discovered role for p53 in normal and cancer stem
cell biology. The genetic pathways regulating stem cell self-re-
newal via symmetric or asymmetric cell divisions has been el-
egantly shown for Drosophila stem cells (Gonzalez, 2007;
Morrison and Kimble, 2006; Neumuller and Knoblich, 2009);
however, the machinery that controls asymmetric versus
symmetric divisions in mammalian stem cells is poorly char-
acterized. Cicalese and colleagues used the power of labeling
cells with a cell-surface dye, PKH26, to follow the fate of
mouse breast stem cells (Cicalese et al., 2009). After labeling
w99% of cells, they noticed onlyw1% of mammosphere cells
retained high levels of PKH26. These PKH26high cells retained
secondary mammosphere formation and outgrowth poten-
tial. By continuously imaging single PKH26high cells in vitro
they found w80% of the first cell divisions were asymmetric.
In contrast, the mammary cells of p53/ mice contained
a higher proportion of mammary stem cells, and in vitro these
cells underwent a higher (w75%) proportion of symmetric cell
divisions. Over time, the number of stem cells increased at an
apparent geometric rate. Similar results were obtained with
ErbB2 over-expressing cells. Restoration of p53 function with
Nutlin3, a small molecule inhibitor of MDM2-dependent p53
degradation, in ErbB2 over-expressing cells switched cell divi-
sions back to asymmetric in the absence of anti-proliferative
effects. Finally, Nutlin3 treatment reduced mammosphere
and tumor formation in ErbB2 over-expressing cells indicating
increased self-renewal contributes to tumor growth. These
studies suggest that the balance between symmetric and
asymmetric CSC self-renewal may be a determinant of CSC
frequency. Therapeutic agents developed to modulate these
pathways may show efficacy in reducing CSC populations.7.2. “Akt”ing as a central node in CSC signaling
Akt (protein kinase B) is a central regulator in the Wnt and
PI3K signaling pathways and is critical in energy homeostasis.
Upstream of Akt is the PTEN tumor suppressor, which en-
codes a lipid and protein phosphatase, and is frequently mu-
tated in human cancer (Keniry and Parsons, 2008). PTEN
dephosphorylates PIP3, a product of PI3K. Loss of PTEN results
in accumulation of PIP3, thereby activating a signaling cas-
cade, including AKT, S6 kinase, mTOR, Rac1, Cdc42, and phos-
phatidylinositol-dependent kinases (Hill and Wu, 2009). AKT
activation results in cell cycle progression via p27 down-regu-
lation and leads to down-regulation of pro-apoptotic factors,
including BAD and caspase-9. Various PTEN mouse models
have shown the PTEN/PI3K/AKT pathway controls stem cell
homeostasis and malignancies in numerous tissues (Guoet al., 2008; Hill and Wu, 2009; Wang et al., 2006a; Yilmaz
et al., 2006; Zhang et al., 2006).
A role for PTEN in breast cancer and stem cells was shown
when it was observed that PTEN deletion inmammary epithe-
lial cells led to precocious mammary gland development and
breast cancer (Li et al., 2002). Germ-line mutation of the
PTEN gene is associated with Cowden’s disease, an autosomal
dominant multi-neoplasia syndrome, which predisposes men
andwomen to an increased risk of breast cancer (Eng, 2003). In
normal human breast tissue, knockdown of PTEN resulted in
increased mammosphere formation, Akt activity, and activa-
tion of the Wnt/b-catenin pathway via GSK3b (Korkaya et al.,
2009). It was observed that PTEN knockdown in humanmam-
mary cells generated disorganized hyperplastic lesions when
these cells were introduced into the humanized mammary
fat pads of NOD/SCID mice. Pharmacological inhibition of
AKT with perifosine, but not the mTOR inhibitor rapamycin,
resulted in fewer mammospheres and completely inhibited
formation of hyperplastic lesions. PTEN knockdown in breast
cancer cells lead to increased mammosphere formation in
vitro and tumor-initiation in NOD/SCID mice. Accordingly,
treatment with the AKT inhibitor perifosine reduced tumor
growth and secondary tumor formation. Previous studies
have shown oncogenic activation of Wnt/b-catenin signaling
increased mammary stem and progenitor cells (Li et al.,
2003; Liu et al., 2004). In agreement, activation of Wnt signal-
ing increased human mammosphere formation (Korkaya
et al., 2009). Taken together, these results suggest that the
PTEN/AKT/Wnt signaling axis regulates normal and malig-
nant breast stem cells.
7.3. Paracrine and autocrine Hedgehog signaling
Aberrant activation of the Hedgehog (Hh) pathway is common
in basal cell carcinoma, medulloblastoma, a tumor of cerebel-
lar granule neuron progenitor cells, and rhabdomyosarcoma,
a muscle tumor. The Hh pathway represents an attractive tar-
get for drug development and has shown promise in Phase I
clinical trials of advanced basal cell carcinoma and medullo-
blastoma with GDC-0449, an Hh pathway inhibitor (Rudin
et al., 2009; Von Hoff et al., 2009). Hh is known to signal
through autocrine, juxtacrine, and paracrine mechanisms
(Rubin and de Sauvage, 2006; Theunissen and de Sauvage,
2009). Secreted Hh (Sonic, Indian, or Dessert) signals through
the 12 trans-membrane Patched 1 (PTCH) receptor, which
de-represses the 7 trans-membrane Smoothened (SMOH) pro-
tein. Translocation of activated SMOH to cilia initiates a signal-
ing cascade resulting in nuclear translocation of active GLI
transcription family members and up-regulation of target
genes including GLI1 and PTCH1.
Given the limited evidence of activating mutations of the
Hh pathway, the role of activated Hh signaling in other solid
tumors had been poorly characterized. Watkins et al. reported
thatw25% of small cell lung cancer (SCLC) samples displayed
high expression of Sonic Hh ligand and GLI1. Inhibition of Hh
signaling with cyclopamine, a natural product SMOH inhibitor
derived from corn lilies, or an anti-Hh antibody blocked
growth of SCLC cell lines in vitro. Furthermore, cyclopamine
prevented growth of SCLC in immunocompromised mice
(Watkins et al., 2003). Hh pathway activation has also been
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Sonic Hh, PTCH1, and SMOH expression in the epithelial and
stromal compartments of human tumors suggesting potential
autocrine and paracrine signaling (Thayer et al., 2003). Treat-
ment with cyclopamine prevented growth of pancreatic cell
lines in vitro and, more importantly, in vivo.
Given the role of Hh signaling in regulating cell prolifera-
tion and differentiation during development, it is not surpris-
ing Hh also regulates normal andmalignant stem cells in both
Drosophila and mammalian systems (Jiang and Hui, 2008). Hh
pathway activation in mouse primitive hematopoietic cells
induced cycling and expansion, but eventual exhaustion of
hematopoietic stem cells (Trowbridge et al., 2006). A role for
Hh signaling in CSC was demonstrated by specific deletion
of Smoothened in BCR-ABL positive chronicmyeloid leukemia
stem cells, which prevented tumor-initiation, and treatment
with cyclopamine increased survival of mice transplanted
with BCR-ABL leukemia cells (Dierks et al., 2008).
Hh signaling also has been shown to play an important role
in normal and malignant breast stem cells. Liu et al. showed
Indian Hh, PTHC1, SMOH, GLI1, and GLI2 are expressed in
stem and progenitor cells when cultured as mammospheres.
Expression of the Hh pathway components was substantially
reducedwhen these cells underwent differentiation (Liu et al.,
2006). Exogenous Hh ligand increased mammosphere forma-
tion whereas cyclopamine treatment inhibited mammo-
sphere formation. Hh signaling induced BMI1 expression
and reduction of BMI1 led to decreasedmammosphere forma-
tion. Furthermore, PTCH1, GLI1, GLI2, and BMI1 were
expressed at higher levels in CD44þCD24 breast CSC com-
pared to bulk cancer cells indicating Hh signaling has a role
in normal and malignant breast stem cells.
7.4. Another notch in CSC defenses?
Notch signaling is activated by binding of Notch receptors
(Notch 1e4) with ligands (Delta, Delta-like, and Jagged1 and
Jagged2) on adjacent cells. Binding initiates a cascade of pro-
teolytic cleavages mediated by members of the ADAM metal-
loprotease family as well as internal cleavage by g-secretase.
Therapeutic inhibition of the Notch pathway can be achieved
by g-secretase inhibitors (GSI), which are currently in clinical
trials for Alzheimer’s disease, T-cell acute lymphoblastic leu-
kemia (T-ALL), and breast cancer. Cleavage results in the
translocation of the Notch intracellular domain (NICD) to the
nucleus where it cooperates with the CSL DNA-binding pro-
tein CBF1/RBPkJ forming a trimeric complex with CBF1/RBPkJ
and the co-activator Mastermind. This induces expression of
Notch target genes including Hes, Hey, c-Myc, cyclin D1, and
p21/Waf1. NICD activity is regulated by CDK8-dependent
phosphorylation thereby resulting in ubiquitination of NICD.
In the absence of NICD, co-repressors, such as CtBP are
recruited. Additionally, Notch activity is inhibited by Numb
through an endocytotic mechanism. Interestingly, Numb is
asymmetrically segregated into one of two daughter cells in
numerous cell types, and is inhibited by Musashi at the level
of Numb mRNA translation (Bray, 2006).
A role for Notch signaling in cancer was demonstrated by
the identification of activating Notch1 mutations in more
than 50% of T-ALL (Weng et al., 2004) and retroviral insertionsinto Notch4 inmousemammary cancers (Jhappan et al., 1992).
Analysis of normal human breast stem cells showed activa-
tion of Notch signaling using soluble Delta ligand promoted
stem cell self-renewal and differentiation of progenitor cells
with negligible effects onmature differentiated epithelial cells
(Dontu et al., 2004). Additionally, it was shown that Musashi1
and Notch1 regulate human breast stem cells (Clarke et al.,
2003, 2005). In the mouse mammary gland, Notch signaling
was shown to regulate the expansion of stem cells and
differentiation to luminal progenitor cells (Bouras et al.,
2008). Recently, Harrison and colleagues showedNotch4 activ-
ity was increased in breast CSC, and that inhibition of Notch4
signaling reduced breast CSCs and completely inhibited
tumor-initiation (Harrison et al., 2010). Interestingly, Notch1
activity was lower in breast CSC compared to more differenti-
ated progenitor cells. This suggests that there is specificity of
different Notch receptors in the regulation of breast stem and
progenitor cells. If this is the case, then selective inhibition of
Notch4 may be more efficacious and potentially less toxic
than Notch1 inhibitors or g-secretase inhibitors that inhibit
all Notch receptors. GSI are currently being evaluated in early
phase clinical trials for advanced breast cancer.
7.5. Cytokine signaling and the tumor
microenvironment
The view of solid tumors as a homogenous sheet of epithelial
cells, such as in vitro culture, is clearly too simplistic. Rather,
tumors are composed of epithelial cells, fibroblasts, endothe-
lial, hematopoietic, and other cells that communicate with
each in a complex network of growth factors and cytokines
and the cognate receptors. The ability to interfere with this
network represents a growing interest in drug discovery. In-
deed, utilization of monoclonal antibodies (i.e. CD44, CD47,
CD123) to inhibit signaling between leukemia stem cells
(LSC) and supporting cells has been very effective at eradicat-
ing AML LSC in NOD/SCID mice (Jin et al., 2006, 2009; Majeti
et al., 2009).
Several cytokines have been implicated in regulating
breast CSCs, including IL-6 (Sansone et al., 2007) and IL-8
and the cognate CXCR1 receptor. CXCR1 expression is higher
in ALDHþ cells from numerous breast cancer cells lines and
exogenous IL-8 increased the CSC population (Charafe-
Jauffret et al., 2009). This suggested that inhibition of IL-8/
CXCR1 signaling could target breast CSC. Ginestier and col-
leagues showed that <2% of breast cancer cells expressed
CXCR1, which overlapped with the ALDHþ fraction (Ginestier
et al., 2010). Interestingly, repertaxin, a small molecule inhib-
itor of CXCR1, was able to decrease viability of the whole pop-
ulation even though only a small fraction expressed CXCR1.
Repertaxin mediated cell killing in the bulk cell population
through a bystander effect via secretion of FAS ligand.
CXCR1 is known to signal through AKT thereby inhibiting
FOXO3A localization, and FAS ligand expression. Repertaxin
treatment inhibited AKT signaling resulting in nuclear
FOXO3A and FAS ligand expression, but, interestingly, was in-
effective in PTEN knockdown cells. Chemotherapy is known to
kill cells via a bystander effect through FAS ligand, but also in-
duces IL-8 and thereby protects CSC from FAS ligand. This
suggested that repertaxin might block this effect and target
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vitro and in tumor xenografts. As a single agent, repertaxin
had marginal effect on tumor growth, but significantly re-
duced tumor volume in combination with the chemotherapy
drug docetaxel. In addition, repertaxin reduced metastatic
burden and secondary tumor formation. Taken together,
these results suggest that repertaxin sensitizes CSC to the by-
stander effect via FAS ligand and that CXCR1 blockade may
represent a new approach to targeting and eliminating breast
CSCs.
7.6. Nothing “micro” about microRNA in CSC signaling
In the 10 years since RNA interference (RNAi) was first de-
scribed by Fire et al. (1998), the field of small RNAs has virtually
exploded. While small-interfering RNA (siRNA) has been ex-
tremely useful as a laboratory tool for silencing target gene ex-
pression (Jackson and Linsley, 2010), the class of microRNAs
(miRNAs) has garnered considerable interest based on the
wide range of possible targets (w300) for each miRNAs
(Bartel, 2009). As of December 2009, over 700 human miRNAs
have been confirmed or predicted within the mirBase data-
base (Griffiths-Jones et al., 2008). miRNAs are endogenous
non-coding w20e23 nt RNAs processed from larger hairpin
structures that bind to complementary sequences in the 30 un-
translated regions (UTR) of mRNAs. Processed miRNAs are
loaded into the Argonaute protein of the silencing complex
(RISC) and pair with mRNAs. Binding is mediated primarily
through a seed sequence of 7e8 nt at the 50 region of the
miRNA via WatsoneCrick pairing. Binding via the seed se-
quence leads to translational repression and/or mRNA desta-
bilization, whereas extensive complementarity, such as
through siRNA, can direct Argonaute-catalyzed mRNA cleav-
age (Bartel, 2009).
The wide range of possible targets for eachmiRNA provides
a simple mechanism for a stem cell to coordinately regulate
a set of “stemness” genes. Deletion of miRNA processing pro-
teins, such as DGCR8 or Dicer, has been shown to alter the G1-
S transition and proliferation of embryonic stem cells (ESC)
(Murchison et al., 2005; Wang et al., 2008). More than 100
miRNAs are differentially expressed between human ESC and
differentiated embryoid bodies (Morin et al., 2008). Indeed,
miR-145 isabsent inself-renewingESCsand targets thepluripo-
tency factorsSox2,Oct4, andKLf4 (Xuetal., 2009). These studies
highlight the importance of miRNAs in regulating “stemness”.
A role for miRNAs in CSC has recently been shown for the
let-7 andmiR-200 families (Shimono et al., 2009;Wellner et al.,
2009; Yu et al., 2007). Yu and colleagues compared miRNA ex-
pression in primary breast cancer cell lines, which were
enriched for mammosphere formation and tumor-initiation,
to more differentiated cancer cells. Let-7 family members
were consistently reduced in the mammosphere cells. Forced
expression of let-7a reduced mammosphere formation in pri-
mary breast cancer and cell lines whereas reduction of let-7a
expression in differentiated cells increased mammosphere
formation. Importantly, forced let-7a expression suppressed
tumor-initiation and growth in NOD/SCID mice and in subse-
quent passages indicating let-7a maintains breast CSCs.
Given the large number of miRNAs present in ESCs com-
pared to differentiated cells (Morin et al., 2008), it is notsurprising that additionalmiRNAs are differentially expressed
in breast CSC. Shimono and colleagues identified 37 miRNAs
up regulated or down regulated in CD44þCD24 breast CSC
compared to bulk, non-tumorigenic cells (Shimono et al.,
2009). Three clusters of miRNAs were down regulated in the
breast CSC, including miR-200c-141, miR-200b-200a-429, and
miRNA-183-96-182. Similar seed sequences are shared be-
tween the miR-200c-141 and miR-200b-200a-429 clusters indi-
cating similar genes are targeted by these miRNAs. These
miRNA clusters were also decreased in normal breast stem
cells suggesting a link between normal and malignant breast
stem cells. Among the numerous targets, Shimono et al. con-
centrated on BMI1 since it is known to regulate normal and
CSCs (Lessard and Sauvageau, 2003; Molofsky et al., 2003;
Park et al., 2003). Exogenous miR-200c reduced BMI1 protein
levels and suppressed growth of embryonal carcinoma cells.
Expression of miR-200c in normal mouse breast stem cells
suppressed outgrowth formation in the mammary fat pad as-
say. Moreover, miR-200c expression in human CD44þCD24
breast CSC also suppressed tumor-initiation in NOD/SCID
mice suggesting similar to let-7 that miR-200c also regulates
breast CSC.
7.7. “Transitioning” from epithelialemesenchymal cells
The epithelialemesenchymal transition (EMT) is a develop-
mental program typically activated in metastatic cancer. Dur-
ing themetastasis process, it is postulated cancer cells acquire
some self-renewal capability to give rise to macroscopic me-
tastases. Mani and colleagues showed forced expression of
Snail or Twist transcription factors, which induce EMT, in-
creased the CD44þCD24 fraction in immortalized human
breast epithelial cells suggesting a relationship between EMT
and the CSC phenotype (Mani et al., 2008). Cells that had un-
dergone EMT had increased mammosphere-forming capacity
and tumor-initiation potential in NOD/SCID mice. The miR-
200 family is known to prevent EMT by suppressing ZEB1
and ZEB2 expression, which are transcriptional repressors of
E-cadherin (Gregory et al., 2008; Park et al., 2008; Wellner
et al., 2009). ZEB1 is also known to inhibit expression of miR-
200 family members creating a double-negative feedback
loop (Bracken et al., 2008; Peter, 2010). Recently, Greene et al.
showed miR-205 is highly expressed in mouse mammary ep-
ithelial progenitors and targets PTEN as well as ZEB1 and
ZEB2 (Greene et al., 2010).
This raises interesting questions about what preventsmiR-
200 expression in stem cells. Wellner and colleagues demon-
strated ZEB1 is expressed in the invasive front of pancreatic
cancer samples (Wellner et al., 2009). Down-regulation of
ZEB1 reduced invasion and metastasis in NOD/SCID mice and
inhibited tumor-initiation and secondary tumor formation.
Furthermore, knockdown of ZEB1 increased expression of
miR-203 and miR-183, members of the miR-200 family, and
forced expression of miR-203 andmiR-183 reduced pancreatic
sphere formation. Examination of the BMI1 30 UTR revealed
binding sites for miR-200, miR-203, and miR-183. It was also
demonstrated that miR-200 also repressed the pluripotency
factors Sox2 and Klf4. Therefore, ZEB1 and the miR-200 family
are at the center of a complexnetwork ofmiRNAsand stemcell
regulators in multiple cancers, including breast cancer.
Figure 1 e High-throughput approaches to target breast CSC. A) Breast CSC can be isolated by sorting using the Aldefluor assay or
CD44DCD24L populations (red box) or via culturing as mammospheres. Within these populations, the CSC frequency is enriched with some
percentage of non-tumorigenic bulk cells remaining. B) To screen the CSC population, cells are plated in 384-well plates in conditions that
maintain tumor-initiation capacity, such as in serum-free suspension (mammosphere) or in EGF- and FGF-containing media on laminin-coated
plates (Pollard et al., 2009). Small molecule compound collections are added to plates at one compound/well, typically at high nanomolar or low
micromolar concentrations. Additionally, the whole genome or selected gene sets (kinases, phosphatases, ‘druggable’) can be targeted using either
siRNA or retroviral or lentiviral shRNA libraries with usually 4e5 constructs per gene. shRNA libraries can provide long-term knockdown
whereas siRNA knockdown is more transient. Cellular endpoints can include growth inhibition (Gupta et al., 2009), flow cytometry (Krutzik and
Nolan, 2006), sphere formation (Diamandis et al., 2007), or cell migration (Wurdak et al., 2010) (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article).
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Figure 2 e Validation of potential “hits” as anti-CSC agents. A) Traditionally, “hits” are identified using a Z- or B-score for each compound/RNA
and at least 3 standard deviations (green line) from the mean (blue line). Hits (red dots) are “cherry-picked” for validation studies (right) at
additional doses to show specificity for CSC (blue circles) and not normal stem cells (red triangles). B) To confirm validated “hits” target CSCs,
activity must be validated using primary tumor xenografts in immunocompromised mice. In the advanced setting (top), cells enriched for breast
CSC are injected into mice, allowed to grow to a palpable size and then mice are treated with candidate drugs or siRNA/shRNA. A CSC-specific
agent (blue triangles) would have minimal effect in this assay since tumor growth is driven primarily by progenitors and not CSC. However, an
agent that targets CSC and the bulk tumor cells (red squares) would show dramatic tumor reduction. This effect could be achieved using a CSC-
specific agent and a chemotherapeutic agent targeting the bulk population. In an early (i.e. adjuvant) setting (bottom), treatment is initiated soon
after injection of CSC-enriched cells. A selective anti-CSC agent (blue triangles) would be predicted to have a much greater effect when
administered in this setting (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article).
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and compounds
Until recently, most drug development targeting CSC was
based on a priori understanding of pathways utilized by these
cells. From a drug discovery standpoint, this strategy is attrac-
tive given the high costs (estimates range from $800million to
$2 billion), high attrition rate, and difficulties associated with
moving a compound from target discovery to FDA approval
(Booth and Zemmel, 2004; Munos, 2009).
Identification of themolecular target(s) for lead compounds
has been extremely time consuming and difficult, but recent
advances point to a future where target identificationmay be-
come more routine. Chemical proteomics, a spectrometry-
based affinity chromatography approach, holds promise for
directly identifying the target protein(s) bound by small mole-
cules, further advancing drug development via new target pro-
teins for subsequent discovery efforts (Rix and Superti-Furga,2009). Computational approachesprovideamechanism topre-
dict molecular targets and potential side-effects (Campillos
et al., 2008; Keiser et al., 2009). Furthermore, development of
databasesofdrugs (MDLDrugDataReport), knowndrug targets
(DrugBank, Matador, SuperTarget), and small molecule gene
expression signature profiles (i.e. Connectivity Map) can pro-
vide new insights into possible mechanisms of action for un-
known compounds (Gunther et al., 2008; Lamb et al., 2006;
Wei et al., 2006; Wishart et al., 2008). The promise of these ap-
proacheswasdemonstratedby in silicodatamining thepublicly
availablemicroarraydatasetswithaquery signature fromAML
cells treated with parthenolide that identified new potential
anti-LSC agents, which were then validated in pre-clinical
models (Hassane et al., 2008).
The combination of high-throughput RNAi screens with
small molecule screens is another avenue to identify the mo-
lecular target(s) of lead compounds (Iorns et al., 2007;
Perrimon et al., 2007; Whitehurst et al., 2007). Identification
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presents new opportunities for drug development, both in
terms of using RNAi as a therapeutic and developing new tar-
gets for small molecule or antibody-based screening. This ap-
proach was recently demonstrated by the screening of the
human kinome in primary glioblastoma cells enriched for tu-
mor-initiation. Schultz and colleagues identified TRRAP, an
adaptor protein with homology to phosphoinositide-3-OH-ki-
nase-related (PIKK) proteins, as critical to self-renewal and
proliferation of brain CSC through effects on cell cycle pro-
gression and histone marks of cyclin A2. Importantly, silenc-
ing of TRRAP suppressed tumorigenicity of primary
xenografts (Wurdak et al., 2010).
The applicability of these screens is not limited to RNAi,
but has also been applied to small molecule libraries (Pollard
et al., 2009). Dirks and colleagues utilized in vitro conditions
that are able to sustain brain tumor-initiating cells. A screen
of 450 compounds that have passed phase IeIII trials identi-
fied the serotonin and monoamine signaling pathways as po-
tential targets for modulation in brain CSCs. These results
mirror previous results showing sensitivity of mouse neuro-
spheres, enriched for stem cell activity, to neurotransmitter
pathway perturbation (Diamandis et al., 2007).
Application of these high-throughput approaches and con-
cepts to breast cancer was recently demonstrated and identi-
fied a previously unrecognized class of compounds with
efficacy against breast CSCs (Gupta et al., 2009). Gupta and col-
leagues harnessed the interesting observation that cells un-
dergoing EMT were enriched for and had characteristics of
CSC (Mani et al., 2008). They used a growth inhibition screen
with breast cells engineered to maintain an EMT state and
the immortalized normal, parental cells. From a collection of
w16,000 small molecules, only 32 targeted the EMT cells and
not the parental cells, and 4 (salinomycin, etoposide, abamec-
tin, and nigericin) were confirmed in follow-up studies. Sali-
nomycin, a potassium ionophore, showed the greatest effect
in vitro by reducing mammosphere formation as well as the
CD44þCD24- fraction, shown previously to include breast
CSC (Al-Hajj et al., 2003). Pre-treatment of breast cancer cells
in vitro with salinomycin dramatically reduced tumor-initia-
tion and lungmetastases in NOD/SCIDmice indicating salino-
mycin was able to target breast CSC. While the mechanism of
action for salinomycin in CSC has not been established, it was
shown recently this compound induced apoptosis in cancer
cells regardless of p53, Bcl2, or multi-drug resistance protein
status and independent of cell cycle arrest, caspase activation,
FAS/FAS ligand, and the proteasome (Fuchs et al., 2009). The
success of these screens highlight the promise of identifying
novel compounds with anti-CSC activity as well as novel pro-
teins and pathways functioning in CSC.8. The future of targeting breast CSC
Currently, there are multiple potential anti-CSC agents in pre-
clinical and clinical trials, including Hh, NOTCH, AKT, and
CXCR1 inhibitors. While these are promising agents, the
likelihood of clinical success will depend onmany aspects, in-
cluding safety, trial design, and rational endpoints. High-
throughput screens represent new avenues for drug discoveryand identification of novel pathways regulating CSCs. Breast
CSCs screens may be based on methods to enrich for CSCs,
such as CD44þCD24, ALDHþ, or sphere formation from cell
lines, primary breast cancer xenografts, or primary samples
(Figure. 1A). These CSC-enriched populations can be used to
screen siRNA, lentiviral shRNA, or small molecule libraries us-
ing various cellular endpoints including growth inhibition
(Gupta et al., 2009), flow cytometry (Krutzik and Nolan,
2006), sphere formation (Diamandis et al., 2007), or cell migra-
tion (Wurdak et al., 2010) (Figure. 1B).
High-throughput screens provide a larger pool of com-
pounds for testing in pre-clinical and clinical models given
the high attrition rate and decreasing productivity within the
pharmaceutical industry (Booth and Zemmel, 2004; Munos,
2009). While some side-effects from chemotherapy agents
are poorly understood, it is increasing clear that others are
due to toxic effects on normal stem cells in various tissues,
suchashematopoietic, skinandgastrointestinal (see ‘The real-
ities of targeting CSCs’ above). Thus, agents identified in pri-
mary high-throughput screens need to be tested on normal
stem cells to remove potentially cytotoxic agents with adverse
side-effects (Figure. 2A). These “confirmed” agents can then be
tested in primary tumor xenograft mouse models, However,
currentmodels, based primarily on tumor growth from rapidly
dividing progenitor cells, are poorly adept to identify anti-CSC
agents, which may have modest growth inhibition effects as
a sole agent (Figure. 2B). Rather, testing agents in an early (i.e.
adjuvant) settingwould identify thoseagentswithanti-CSCac-
tivity since early tumor formation is stem cell dependent.
New therapies might come from traditional or existing
medicines that were not tested for anti-cancer efficacy and
can be rapidly “repurposed” (Chen et al., 2008; Chong and
Sullivan, 2007; Eberhard et al., 2009; Ginestier et al., 2010).
The CXRC1 inhibitor repertaxin was developed to block organ
transplant rejection, the gamma-secretase inhibitors initially
developed to treat Alzheimer’s disease, and anti-fungal ciclo-
pirox olamine recently shown to target AML LSCs are exam-
ples of “repurposing” existing medicines.
Many proteins are considered “undruggable” based on cel-
lular location, binding, and function (i.e. transcription factors)
(Overington et al., 2006). The promise of RNAi is great consid-
ering the ability to target these “undruggable” proteins. How-
ever, RNAi has limitations, including off-target effects,
immune system modulation, and issues related to in vivo de-
livery (Jackson and Linsley, 2010; Whitehead et al., 2009). Sys-
temic delivery, via intravenous injection, is likely required for
treatment of disseminated disease and requires the ability to
avoid non-target tissues and efficient delivery to CSCs. The
ability to bypass kidney filtration, phagocytosis, aggregation
in serum, and enzymatic degradation is a key to successful
RNAi therapy with numerous groups and companies actively
trying to solve these issues. Indeed, RNAi therapeutics are cur-
rently in clinical trials for various diseases, such as age-related
macular degeneration, but most current trials rely on local-
ized delivery instead of using delivery agents (Whitehead
et al., 2009).
Much progress has been made in targeting CSC since the
“original” discovery in AML (Lapidot et al., 1994) and the iden-
tification of parthenolide as an anti-LSC agent (Guzman et al.,
2005). Recent advances in understanding the pathways
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citing pre-clinical and phase I clinical trials to test the clinical
relevance of CSC. In addition, improved in vitro culture
methods to maintain CSC activity from primary tumor sam-
ples open the arena of high-throughput screening of small
molecule and siRNA libraries. Initial results from these
screens have provided new clues and leads in the fight against
cancer. Taken together, these studies provide novel agents to
target this critical cell population. It is hoped that successful
targeting of CSCwill significantly improve the outcome for pa-
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